在慢性心力衰竭中重复使用levosimendan的安全性
Irina Semenycheva1, Svetlana Larina2, Larisa Zakharova3
1Department of Digital Technologies in Healthcare, Sechenov First Moscow State Medical University, Moscow, Russia.
Journal of cardiovascular pharmacology
|January 22, 2026
概括
与levosimendan和dapagliflozin的联合治疗显著改善了慢性心力衰竭 (CHF) 患者的临床结果. 与单疗法或安慰剂相比,这种方法减少了住院治疗和提高了生活质量.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 慢性心力衰竭 (CHF) 降低喷射率 (<40%) 仍然是一个重要的临床挑战.
- 优化心血管疾病门诊患者的治疗策略对于改善治疗结果至关重要.
研究的目的:
- 评估单独或与达帕格利弗洛辛联合多次服用levosimendan的临床疗效和安全性. 在CHF门诊患者中.
- 为了比较组合治疗与levosimendan单一治疗和安慰剂对关键临床标志物的影响.
主要方法:
- 这是一项多中心,随机,双盲,安慰剂控制的试验,涉及393名心血管疾病门诊患者.
- 患者接受了levosimendan单疗法,安慰剂或组合疗法 (levosimendan加达帕格利弗洛辛).
- 主要结局包括NT-proBNP水平和住院率;次要结局评估生活质量 (MLHFQ) 和安全.
主要成果:
- 组合疗法显示出最大的临床益处,显著降低了NT-proBNP和住院率 (p=0.03,p=0.04).
- 组合组显示出住院或死亡的风险明显降低 (HR=0.58,p=0.021) 以及生活质量改善的优势.
- 莱沃西门丹单一疗法提供了中等效益,总是比组合疗法少.
结论:
- 列沃西门丹和达帕格利弗洛辛的组合为心血管疾病门诊患者提供了卓越的临床益处.
- 这种组合有效地减少了住院治疗,改善了生活质量,同时保持了有利的安全性.
- 这种疗法代表了治疗慢性心力衰竭的有希望的治疗选择,减少了喷射分数.
相关概念视频
01:29Heart Failure II: Pathophysiology
790
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
790
01:17Pathophysiology of Heart Failure
3.0K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.0K
01:27Heart Failure I: Introduction
729
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
729
01:22Heart Failure VI: Adjunct Therapies
278
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
278
01:22Heart Failure Drugs: Diuretics
825
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
825
01:30Heart Failure V: Medical Management
227
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
227